Mergers and acquisitions in the biotech sector often create optimism among investors as they can lead to synergies and an expanded product pipeline. AVROBIO's acquisition of Tectonic Therapeutic is likely to be seen as a positive strategic move, potentially leading to a short-term increase in AVRO's stock price. However, the long-term impact will depend on the successful integration of Tectonic's technology and the development of the expanded pipeline.